SG Americas Securities LLC Buys 14,272 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

SG Americas Securities LLC grew its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 106.2% during the third quarter, Holdings Channel reports. The firm owned 27,706 shares of the biotechnology company’s stock after purchasing an additional 14,272 shares during the period. SG Americas Securities LLC’s holdings in Anavex Life Sciences were worth $157,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its position in Anavex Life Sciences by 8.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 2,401 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new stake in shares of Anavex Life Sciences in the 2nd quarter worth $346,000. AQR Capital Management LLC raised its holdings in shares of Anavex Life Sciences by 145.8% in the second quarter. AQR Capital Management LLC now owns 45,219 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 26,821 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Anavex Life Sciences during the second quarter valued at about $191,000. Finally, Marshall Wace LLP bought a new position in shares of Anavex Life Sciences during the second quarter valued at about $166,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock opened at $5.33 on Friday. The firm has a market cap of $451.14 million, a PE ratio of -10.66 and a beta of 0.61. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $10.45. The stock has a fifty day moving average price of $5.61 and a 200-day moving average price of $4.98.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same quarter in the previous year, the company posted ($0.14) EPS. As a group, equities analysts anticipate that Anavex Life Sciences Corp. will post -0.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on AVXL. EF Hutton Acquisition Co. I upgraded shares of Anavex Life Sciences to a “strong-buy” rating in a research note on Monday, July 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a report on Friday, October 18th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.